---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-23-000042"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2023-12-07T23:59:59+00:00"
generated_at: "2026-06-07T16:00:26.131483+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Edwards plans tax-free spin-off of Critical Care, issues 2024 sales guidance $6.3-6.6B

## Summary
- Edwards plans tax-free spin-off of Critical Care at end of 2024; Katie Szyman to be CEO of new company.
- 2024 guidance: sales $6.3-6.6B (8-10% constant currency growth), adjusted EPS $2.70-2.80.
- 2024 TAVR sales $4.0-4.3B (8-10% growth); TMTT sales $280-320M.
- Board authorized $1B additional share repurchase authorization.
- Clinical milestones: PROGRESS enrollment complete early 2024, EARLY TAVR data at TCT 2024, EVOQUE US approval mid-2024.

## SEC filing metadata
- accession: 0001099800-23-000042
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2023-12-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980023000042/0001099800-23-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980023000042/ew-20231207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-23-000042
- JSON: https://secwatch.observer/filing/0001099800-23-000042.json
- Plain text: https://secwatch.observer/filing/0001099800-23-000042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.